Kyntra Bio, Inc.
KYNBHealthcare|Biotechnology|US
$3.73
+0.07 (+1.91%)
DCF Value
$12.09
Cash / Share
$22.56
About
Kyntra Bio, Inc. functions as a biopharmaceutical enterprise, encompassing the entire process from the initial discovery and rigorous development of innovative treatments to their ultimate market introduction. The company's scientific focus delves into the complex biology of hypoxia-inducible factors (HIF) and connective tissue growth factors (CTGF). Through this research, Kyntra Bio strives to create groundbreaking therapies aimed at tackling conditions like anemia, various fibrotic disorders, and different forms of cancer. Established by Thomas B. Neff on September 29, 1993, the firm's main offices are situated in San Francisco, California.
Stock Price
-66.1%(1Y)
1M
-37.4%
3M
-48.7%
6M
-46.3%
YTD
-57.5%
1Y
-66.1%
3Y
-68.7%
5Y
-98.8%
Pipeline Summary
62 total trials17
Phase 1
19
Phase 2
28
Phase 3
1
Phase 4
Completed: 47Terminated: 10Recruiting: 2Active: 1Not Yet Recruiting: 1Withdrawn: 1
Active Trials (3)
Imaging Study of [89Zr]DFO-YS5 for Cancer Detection
NCT07664397Bladder Cancer
Phase 1Recruiting
Enrollment: 40 participants
FOR46 in Combination With Enzalutamide in Patients With Metastatic Castration Resistant Prostate Cancer
NCT05011188Metastatic Castration-resistant Prostate Cancer
Phase 1Phase 2Active
Enrollment: 44 participants
A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT06842498Metastatic Castration-Resistant Prostate Cancer
Phase 2Recruiting
Enrollment: 75 participants
Key Facts
Market Cap$15.1M
Employees34 (-35% YoY)
CEOThane Wettig
IPO DateNov 14, 2014
Beta1.10
52-Week Range$3.6 – $11.19
Avg Volume19,208
ExchangeNASDAQ
Websitekyntrabio.com
Ownership
Float88.1%
Shares Outstanding4.0M
Recent Insider Trades
Singer Andrew E.AWARD
Oct 1, 202614,000 shares @ $6.50
Singer Andrew E.OTHER
Oct 1, 20260 shares
Wettig ThaneTAX W/H
Sep 6, 2026209 shares @ $8.55
DeLucia DavidTAX W/H
Sep 6, 202622 shares @ $8.55
Ho MaykinAWARD
Jun 12, 20267,000 shares @ $7.13
Peers
Recent News
Immatics (NASDAQ:IMTX) vs. Kyntra Bio (NASDAQ:KYNB) Financial Contrast
Oct 9, 2026 · defenseworld.net
Kyntra Bio Appoints Andrew E. Singer, MBA to its Board of Directors
Oct 1, 2026 · globenewswire.com
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Sep 2, 2026 · globenewswire.com
Kyntra Bio Continues Balance Sheet Transformation with Material Reduction of Royalty Financing Obligation
Aug 31, 2026 · globenewswire.com
Kyntra Bio, Inc. (KYNB) Q2 2026 Earnings Call Transcript
Aug 14, 2026 · seekingalpha.com
Data last updated: Nov 9, 2026, 04:19 AM